Clinical Stage I Seminoma Germ Cell Tumour: What to Do When Adjuvant Therapy Has Not Prevented Relapse

This protocol covers the management of seminoma germ cell tumour confined to the testis (clinical stage I) in patients who have relapsed after initial adjuvant treatment. The appropriate next step depends on the prior therapy received and the risk classification at the time of relapse.

Clinical Scenario

Seminoma germ cell tumour, clinical stage I: tumour limited to the testis, no regional lymph node metastasis, no distant metastasis. Although patients with CS I seminoma generally carry a low risk of recurrence, relapse after adjuvant treatment is a defined clinical event requiring a structured next-line approach.

Prior Treatment & Failure Condition

The previous line consisted of either adjuvant carboplatin or, in highly selected patients unsuitable for systemic chemotherapy, adjuvant radiotherapy. This line is considered to have failed when the target state is not maintained: normal serum tumour markers (AFP, hCG, LDH) and no evidence of relapse on cross-sectional imaging.

Next-Line Approach

Standard cisplatin-based chemotherapy, selected according to IGCCCG prognostic risk group, is the indicated approach following relapse. The specific regimen and number of cycles are determined by the risk category at the time of salvage.

Complete regimen details, risk stratification criteria, and sequencing are available in the structured protocol below.

Instant Access to Structured Evidence-Based Regimens

References

Management options for CS I SGCTs include surveillance and adjuvant chemotherapy.

Patients with CS I SGCT have, in general, a low risk of recurrence.

Most patients relapsing after adjuvant carboplatin can be successfully treated by standard, stage-adapted cisplatin-based chemotherapy.

View source ↗